EUCTR2005-002380-90-DK进行中（未招募）不适用
Effekten af intravenøs infusion af n-3 polyumættede fedtsyrer på risikomarkører for pludselig hjertedød hos hæmodialysepatienter
yremedicinsk afdeling, Aalborg Sygehus0 个研究点目标入组 70 人开始时间: 2005年8月24日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with chronic renal failure undergoing haemodialysis treatment three times a week
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Allergy to fish or egg protein. Age < 18 yrs. Body Weight < 50 kg. Chronic supraventricular arrhythmias. Implanted pacemaker. Myocardial infarction or stroke within the past 6 months. Tendency to significant drop in bloodpressure during haemodialysis. Ongoing infection. Other serious illness. Fasting triglycerides > 3 mmol/L.
研究者
相似试验
已完成
2 期
Evaluation of the subcutaneous administration of 30 mg of S78989 versus placebo and evaluation of the subcutaneous administration of 60mg of S78989 versus placebo, on the reduction of arterial wall inflammation in patients with marked atherosclerotic plaque inflammation. A 28-weeks, randomized, double-blind, parallel-group, placebo controlled, international multicenter exploratory pilot study.arterial wall inflammationartherosclerosis10003216NL-OMON39440I.R.I.S22
进行中（未招募）
不适用
Evaluation of administration of gevokizumab versus placebo on the reduction of atheroma plaque inflammation.Arterial wall inflammation in patients with marked atherosclerotic plaque inflammationMedDRA version: 14.1Level: LLTClassification code 10057703Term: Coronary atherosclerosis of non-autologous biological bypass graftSystem Organ Class: 100000004849MedDRA version: 14.1Level: LLTClassification code 10058152Term: Coronary atherosclerosis of bypass graftSystem Organ Class: 100000004849MedDRA version: 14.1Level: LLTClassification code 10018104Term: Generalized and unspecified atherosclerosisSystem Organ Class: 100000004866MedDRA version: 14.1Level: LLTClassification code 10002892Term: Aortic atherosclerosisSystem Organ Class: 100000004866MedDRA version: 14.1Level: LLTClassification code 10011093Term: Coronary atherosclerosisSystem Organ Class: 100000004849MedDRA version: 14.1Level: LLTClassification code 10003603Term: Atherosclerosis generalizedSystem Organ Class: 100000004866MedDRA version: 14.1Level: LLTClassification code 10011095Term: Coronary atherosclerosis of native coronary arterySystem Organ Class: 100000004849MedDRA version: 14.1Level: LLTClassification code 10003605Term: Atherosclerosis of aortaSystem Organ Class: 100000004866MedDRA version: 14.1Level: LLTClassification code 10051615Term: Atherosclerotic cardiovascular diseaseSystem Organ Class: 100000004866MedDRA version: 14.1Level: LLTClassification code 10011094Term: Coronary atherosclerosis of autologous biological bypass graftSystem Organ Class: 100000004849MedDRA version: 14.1Level: LLTClassification code 10011076Term: Coronary artery atherosclerosisSystem Organ Class: 100000004849MedDRA version: 14.1Level: LLTClassification code 10011097Term: Coronary atherosclerosis of unspecified vesselSystem Organ Class: 100000004849EUCTR2012-002677-53-NLInstitut de Recherches Internationales Servier (I.R.I.S.)45
进行中（未招募）
不适用
Evaluation of administration of gevokizumab versus placebo on the reduction of atheroma plaque inflammation.Arterial wall inflammation in patients with marked atherosclerotic plaque inflammationMedDRA version: 16.0Level: LLTClassification code 10057703Term: Coronary atherosclerosis of non-autologous biological bypass graftSystem Organ Class: 100000004849MedDRA version: 16.0Level: LLTClassification code 10058152Term: Coronary atherosclerosis of bypass graftSystem Organ Class: 100000004849MedDRA version: 16.0Level: LLTClassification code 10018104Term: Generalized and unspecified atherosclerosisSystem Organ Class: 100000004866MedDRA version: 16.0Level: LLTClassification code 10002892Term: Aortic atherosclerosisSystem Organ Class: 100000004866MedDRA version: 16.0Level: LLTClassification code 10011093Term: Coronary atherosclerosisSystem Organ Class: 100000004849MedDRA version: 16.0Level: LLTClassification code 10003603Term: Atherosclerosis generalizedSystem Organ Class: 100000004866MedDRA version: 16.0Level: LLTClassification code 10011095Term: Coronary atherosclerosis of native coronary arterySystem Organ Class: 100000004849MedDRA version: 16.0Level: LLTClassification code 10003605Term: Atherosclerosis of aortaSystem Organ Class: 100000004866MedDRA version: 16.0Level: LLTClassification code 10051615Term: Atherosclerotic cardiovascular diseaseSystem Organ Class: 100000004866MedDRA version: 16.0Level: LLTClassification code 10011094Term: Coronary atherosclerosis of autologous biological bypass graftSystem Organ Class: 100000004849MedDRA version: 16.0Level: LLTClassification code 10011076Term: Coronary artery atherosclerosisSystem Organ Class: 100000004849MedDRA version: 16.0Level: LLTClassification code 10011097Term: Coronary atherosclerosis of unspecified vesselSystem Organ Class: 100000004849EUCTR2012-002677-53-FIInstitut de Recherches Internationales Servier (I.R.I.S.)90
招募中
2 期
A Study of The Effect of Magnesium Sulfate on End-Tidal CO2 and PaiEnd-Tidal CO2.IRCT20210302050549N1Rafsanjan University of Medical Sciences62
尚未招募
不适用
The effect of IV iron on the gut microbiome in patients with metastatic colorectal cancerNeoplasmsKCT0007895Korea University Anam Hospital60